Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 14/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10724239 | 0.88 | EPHX1 (0.48) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL8303799 | 0.87 | EPHX1 (0.42) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL8303797 | 0.87 | EPHX1 (0.42) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL5605365 | 0.84 | GPR84 (0.47) | EPHX1ACHE | |
| SCHEMBL14076726 | 0.84 | EPHX1 (0.47) | EPHX1ACHEALDH1A1 | |
| SCHEMBL8322165 | 0.83 | EPHX1 (0.44) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL13503781 | 0.83 | MAPK1 (0.40) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL12606830 | 0.82 | NPC1 (0.43) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL19837622 | 0.82 | EPHX1 (0.38) | EPHX1ACHEALDH1A1NPC1HPGD | |
| SCHEMBL9359582 | 0.81 | ACHE (0.45) | EPHX1ACHENPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017123616-A1 | INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |